Related Experiment Video

Updated: Jun 11, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

From the bench to the bed side: PI3K pathway inhibitors in clinical development

Saveur-Michel Maira1, Peter Finan, Carlos Garcia-Echeverria

  • 1Oncology Drug Discovery, Novartis Institutes for Biomedical Research, Vitry-sur-Seine Cedex, France.

Current Topics in Microbiology and Immunology
|June 29, 2010
PubMed

Insights

New anticancer drugs targeting the PI3K/Akt/mTOR pathway are emerging. This review covers compounds that modulate PI3K, Akt, mTOR, and Hsp90 activity for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is crucial in cell growth and survival.
  • Dysregulation of this pathway is common in various cancers, making it a prime target for anticancer therapies.

Purpose of the Study:

  • To review the progress in identifying and clinically evaluating novel anticancer agents.
  • To focus on compounds that modulate the enzymatic activity of key pathway components: PI3K, Akt, mTOR, and heat shock protein 90 (Hsp90).

Main Methods:

  • Literature review of recent scientific publications and clinical trial data.
  • Analysis of compounds targeting specific kinases within the PI3K/Akt/mTOR pathway.
  • Evaluation of Hsp90 inhibitors in the context of this pathway.

Main Results:

  • Several novel compounds targeting PI3K, Akt, and mTOR have been identified and are in various stages of clinical evaluation.
  • Hsp90 inhibitors show promise by stabilizing key pathway components and enhancing drug efficacy.
  • These targeted agents demonstrate specific disruption of the PI3K/Akt/mTOR pathway in tumor cells.

Conclusions:

  • Targeting the PI3K/Akt/mTOR pathway with novel kinase inhibitors represents a significant advancement in cancer therapy.
  • Modulating PI3K, Akt, mTOR, and Hsp90 offers a promising strategy for developing effective and specific anticancer agents.
  • Continued clinical evaluation is essential to establish the full therapeutic potential of these targeted compounds.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...